📣 VC round data is live. Check it out!

Fulcrum Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Fulcrum Therapeutics and similar public comparables like Karyopharm Therapeutics, Atrium Therapeutics, Saniona, BioInvent International and more.

Fulcrum Therapeutics Overview

About Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.


Founded

2015

HQ

United States

Employees

55

Financials (LTM)

Revenue: -
EBITDA: ($72M)

Market Cap

$209M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Fulcrum Therapeutics Financials

Fulcrum Therapeutics reported last 12-month revenue of - and negative EBITDA of ($72M).

In the same LTM period, Fulcrum Therapeutics generated - in gross profit, ($72M) in EBITDA losses, and had net loss of ($70M).

Revenue (LTM)


Fulcrum Therapeutics P&L

In the most recent fiscal year, Fulcrum Therapeutics reported revenue of - and EBITDA of ($83M).

Fulcrum Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Fulcrum Therapeutics
LTMLast FY202320242025202620272028
Revenue--$3M$80M-
EBITDA($72M)($83M)($108M)($18M)($83M)
EBITDA Margin--(3868%)(23%)-
EBIT Margin--(3945%)(25%)-
Net Profit($70M)($75M)($97M)($10M)($75M)
Net Margin--(3470%)(12%)-

Financial data powered by Morningstar, Inc.

Fulcrum Therapeutics Stock Performance

Fulcrum Therapeutics has current market cap of $209M.

Market Cap Evolution


Fulcrum Therapeutics' stock price is $3.14.

Fulcrum Therapeutics share price decreased by 54.6% in the last 30 days, and by 54.3% in the last year.

Fulcrum Therapeutics has an EPS (earnings per share) of $-1.12.

See more trading valuation data for Fulcrum Therapeutics
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$209M-51.0%-54.6%-59.1%-54.3%$-1.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Fulcrum Therapeutics Valuation Multiples

Fulcrum Therapeutics trades at 1.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Fulcrum Therapeutics

EV / Revenue (LTM)


Fulcrum Therapeutics Financial Valuation Multiples

As of June 4, 2026, Fulcrum Therapeutics has market cap of $209M.

Fulcrum Therapeutics has a P/E ratio of (3.0x).

LTMLast FY202320242025202620272028
EV/Revenue--(42.1x)(1.5x)-
EV/EBITDA1.6x1.4x1.1x6.5x1.4x
EV/EBIT1.5x1.4x1.1x6.0x1.4x
P/E(3.0x)(2.8x)(2.1x)(21.5x)(2.8x)
EV/FCF2.0x2.0x1.3x47.4x2.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Fulcrum Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Fulcrum Therapeutics Margins & Growth Rates

Fulcrum Therapeutics decreased EBITDA by 31% in the last fiscal year.

See estimated margins and future growth rates for Fulcrum Therapeutics

Fulcrum Therapeutics Margins

2024202720282029
EBITDA Margin(23%)
EBIT Margin(25%)
Net Margin(12%)
FCF Margin(3%)

Fulcrum Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth-2752%(100%)-
EBITDA Growth(31%)(83%)357%(31%)
EBIT Growth(13%)(82%)327%(13%)
Net Profit Growth(14%)(90%)670%(14%)
FCF Growth(1%)(97%)2319%(1%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Fulcrum Therapeutics Operational KPIs

Fulcrum Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.5M for the same period.

Access forward-looking KPIs for Fulcrum Therapeutics
Last FY20232024202620272028
Revenue per Employee$0.0M--
Opex per Employee$1.5M--
G&A Expenses to Revenue-1485%46%
R&D Expenses to Revenue-2560%79%
Opex to Revenue-4045%125%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Fulcrum Therapeutics Competitors

Fulcrum Therapeutics competitors include Karyopharm Therapeutics, Atrium Therapeutics, Saniona, BioInvent International, Keros Therapeutics, Nkarta, Whitehawk Therapeutics, Camp4 Therapeutics, NervGen Pharma and Foghorn Therapeutics.

Most Fulcrum Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Karyopharm Therapeutics2.4x2.5x(2.3x)-
Atrium Therapeutics(3.0x)(3.0x)0.7x-
Saniona3.2x-4.5x7.5x
BioInvent International6.4x7.6x(4.8x)(3.6x)
Keros Therapeutics(0.2x)(0.4x)(0.8x)-
Nkarta--(0.5x)-
Whitehawk Therapeutics8.5x14.8x(3.0x)-
Camp4 Therapeutics31.3x24.2x(2.2x)(1.5x)

This data is available for Pro users. Sign up to see all Fulcrum Therapeutics competitors and their valuation data.

Start Free Trial

Fulcrum Therapeutics VC Funding History

Before going public, Fulcrum Therapeutics raised $140M in total equity funding, across 3 rounds.

Last private valuation of Fulcrum Therapeutics was $534M, after raising $80M in September 2018 from 6 Dimensions Capital, Casdin Capital, Fidelity, and 5 other investors.


Fulcrum Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Sep-18Series B6 Dimensions Capital; Casdin Capital; Fidelity; Foresite Capital; Leerink Partners; NS Investment; S32; Sanofi$80M$534MFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to unlock gene control for treating serious genetic diseases, particularly rare neuromuscular disorders like facioscapulohumeral muscular dystrophy (FSHD). On September 5, 2018, the company closed an $80 million Series B financing round led by Foresite Capital, with participation from Fidelity Management and Research Company, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments, entities affiliated with Leerink Partners, and undisclosed investors. Proceeds were allocated to advance its lead FSHD program into clinical testing and progress its pipeline for genetically-based neuromuscular, central nervous system, and hematologic disorders. Jim Tananbaum, M.D., from Foresite Capital joined the board. This Series B was part of Fulcrum's total pre-IPO equity funding of approximately $140 million across four rounds, including a $55 million Series A from Third Rock Ventures in 2016 and a Series A extension in 2017. Fulcrum went public in July 2019, raising $72 million in an IPO, which provided exits for investors like Sanofi, 6 Dimensions Capital, and GSK (whose stake diluted from 9.5% to 7.7%). Post-IPO, proceeds supported a phase 2b trial of Losmapimod (licensed from GSK) for FSHD, with $45 million allocated, plus funds for haemoglobinopathies treatments and drug discovery. Third Rock remained the largest shareholder at 34.9%, and Foresite held 6.4%.
May-17Series AGV$5M-Fulcrum Therapeutics focuses on small molecule therapies that modulate gene regulation for serious genetic diseases. Launched by Third Rock Ventures in 2016, Fulcrum was named a Fierce 15 company that year. Fulcrum Therapeutics secured additional Series A funding from GV on May 10, 2017, to advance its lead programs in Fragile X syndrome and facioscapulohumeral muscular dystrophy.
Jul-16Series AThird Rock Ventures$55M-Fulcrum Therapeutics is a biotechnology company focused on developing small molecule therapies that modulate gene regulation by targeting on/off control mechanisms of disease genes, particularly in genetic diseases. The company was launched on July 19, 2016, with a $55 million Series A financing solely from Third Rock Ventures to build its cross-disciplinary product engine and advance initial programs in areas such as Fragile X syndrome and muscular dystrophy toward clinical trials. Fulcrum's approach leverages pluripotent stem cells derived from patient skin to model disease processes involving altered gene expression, aiming to restore balance in monogenic disorders through small molecule modulation. Led by President and CEO Robert J. Gould, Ph.D., formerly of Epizyme, the company seeks to create a robust pipeline across therapeutic areas in neuromuscular, central nervous system, and hematologic disorders. The Series A funding enabled platform development and progression of lead programs. Subsequent rounds included an $80 million Series B in 2018 led by Foresite Capital with participation from Sanofi Ventures and others, supporting clinical trials for facioscapulohumeral muscular dystrophy (FSHD) and further pipeline expansion.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Fulcrum Therapeutics

When was Fulcrum Therapeutics founded?Fulcrum Therapeutics was founded in 2015.
Where is Fulcrum Therapeutics headquartered?Fulcrum Therapeutics is headquartered in United States.
How many employees does Fulcrum Therapeutics have?As of today, Fulcrum Therapeutics has over 55 employees.
Who is the CEO of Fulcrum Therapeutics?Fulcrum Therapeutics' CEO is Alex C. Sapir.
Is Fulcrum Therapeutics publicly listed?Yes, Fulcrum Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Fulcrum Therapeutics?Fulcrum Therapeutics trades under FULC ticker.
When did Fulcrum Therapeutics go public?Fulcrum Therapeutics went public in 2019.
Who are competitors of Fulcrum Therapeutics?Fulcrum Therapeutics main competitors include Karyopharm Therapeutics, Atrium Therapeutics, Saniona, BioInvent International, Keros Therapeutics, Nkarta, Whitehawk Therapeutics, Camp4 Therapeutics, NervGen Pharma, Foghorn Therapeutics.
What is the current market cap of Fulcrum Therapeutics?Fulcrum Therapeutics' current market cap is $209M.
Is Fulcrum Therapeutics profitable?No, Fulcrum Therapeutics is not profitable.
What is the current EBITDA of Fulcrum Therapeutics?Fulcrum Therapeutics has negative EBITDA and is not profitable.
What is the current EV/EBITDA multiple of Fulcrum Therapeutics?Current EBITDA multiple of Fulcrum Therapeutics is 1.6x.
What is the current FCF of Fulcrum Therapeutics?Fulcrum Therapeutics' last 12 months FCF is ($60M).
What is the current EV/FCF multiple of Fulcrum Therapeutics?Current FCF multiple of Fulcrum Therapeutics is 2.0x.
How many companies Fulcrum Therapeutics has acquired to date?Fulcrum Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Fulcrum Therapeutics has invested to date?Fulcrum Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Fulcrum Therapeutics

Lists including Fulcrum Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial